N-803 with or without bNAbs for HIV-1 Control in Participants Living with HIV-1 on Suppressive ART

Infectious Disease

Official Title

A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Purpose

This study will evaluate the safety, tolerability, and efficacy of N-803 with or without bNAbs, to induce HIV-1 control during an analytic treatment interruption (ATI).

Could this study be right for you?

  • HIV RNA <50 for at least 96 weeks
  • On a stable ART regimen for at least 96 weeks
  • CD4 count above 500
  • No known history of CD4 count below 200
  • Willingness to participate in analytic treatment interruption (ATI)

Age Range

18 - 70 years